<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02539511</url>
  </required_header>
  <id_info>
    <org_study_id>7014</org_study_id>
    <secondary_id>R21AA023010</secondary_id>
    <nct_id>NCT02539511</nct_id>
  </id_info>
  <brief_title>Glutamatergic Modulation of Disordered Alcohol Use</brief_title>
  <official_title>The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol use disorders remain a significant public health problem. The pharmacological
      facilitation of behavioral treatment represents a promising strategy for addressing
      disordered drinking. Alcohol use disorders are recognized to be associated with various
      vulnerabilities that complicate the course of treatment and that may be amenable to glutamate
      modulators. The purpose of this randomized, double-blind, controlled trial is to test various
      glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol
      use disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals diagnosed with alcohol dependence will be randomized to receive a single infusion
      of glutamate modulators during week 2 while engaged in a 5-week course of MET. They will meet
      with staff twice weekly, except for week 2 during which they will present to the clinic three
      times. Clinic visits include MET sessions, psychiatric monitoring, assessments, and study
      procedures (e.g., medication administration).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group</measure>
    <time_frame>21 days post-infusion</time_frame>
    <description>Percentage of participants demonstrating alcohol abstinence in the control (midazolam) group versus the active (ketamine) group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>CI-581a+MET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CI-581b+MET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-581a</intervention_name>
    <arm_group_label>CI-581a+MET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-581b</intervention_name>
    <arm_group_label>CI-581b+MET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Enhancement Therapy (MET)</intervention_name>
    <arm_group_label>CI-581a+MET</arm_group_label>
    <arm_group_label>CI-581b+MET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active alcohol dependence. In the case of the use of other drugs, alcohol is
             designated as the primary drug. At least four heavy drinking day over the past 7 days
             (&gt;4 drinks a day for males, &gt;3 drinks for females) OR minimum weekly use of 35 drinks
             for males and 28 for females

          -  Physically healthy

          -  No adverse reactions to study medications

          -  21-69 years of age

          -  Capacity to consent and comply with study procedures, including sufficient proficiency
             in English

          -  Seeking to reduce or stop alcohol use

        Exclusion Criteria:

          -  Meets criteria for current major depression, bipolar disorder, schizophrenia, any
             psychotic illness, including substance induced psychosis, and current
             substance-induced mood disorder.

          -  Physiological dependence on another substance requiring medical management, such as
             opiods or benzodiazepines, excluding caffeine, nicotine, and cannabis

          -  Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders.
             Significant dissociative symptoms

          -  Current suicide risk or a history of suicide attempt within the past year

          -  Inability to safely initiate 24 hours of abstinence from alcohol; repeated inability
             to initiate abstinence during the trial without incurring significant withdrawal;
             history of severe withdrawal phenomena over the past 6 months (e.g.,
             withdrawal-related seizure); or self-reported inability to maintain abstinence for 24
             hours without substantial distress.

          -  Pregnant or interested in becoming pregnant during the study period

          -  Any of the following cardiac conditions: clinically significant left ventricular
             hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse

          -  Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), leukopenia, active hepatitis or other liver disease with
             elevated transaminase levels (&lt; 2-3 X upper limit of normal will be considered
             acceptable if clotting factors are normal), renal failure, epilepsy, or untreated
             diabetes

          -  Previous history of study medication misuse or abuse, and a history of an adverse
             reaction/experience with prior exposure to study medications

          -  Recent history of significant violence (past 2 years)

          -  First degree relative with a psychotic disorder (bipolar disorder, schizophrenia,
             schizoaffective disorder, or psychosis NOS)

          -  obesity

          -  On psychotropic or other medications whose effect could be disrupted by participation
             in the study

          -  BMI &gt; 35
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Dakwar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI/Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYSPI</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2015</study_first_posted>
  <results_first_submitted>January 25, 2019</results_first_submitted>
  <results_first_submitted_qc>April 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elias Dakwar</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02539511/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02539511/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>50 participants were enrolled in the study and from those, 40 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group: Midazolam+MET</title>
          <description>50-minute intravenous infusion of the active control midazolam (0.025 mg/kg), administered during the second week of a five week regimen of motivational enhancement therapy.</description>
        </group>
        <group group_id="P2">
          <title>Active Group: Ketamine+MET</title>
          <description>50-minute intravenous infusion of ketamine (0.71 mg/kg) administered during the second week of a five week regimen of motivational enhancement therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>40 adults with DSM-IV alcohol dependence without significant medical or psychiatric co-morbidity.</population>
      <group_list>
        <group group_id="B1">
          <title>Control Group: Midazolam+MET</title>
          <description>50-minute intravenous infusion of the active control midazolam (0.025 mg/kg), administered during the second week of a five week regimen of motivational enhancement therapy.</description>
        </group>
        <group group_id="B2">
          <title>Active Group: Ketamine+MET</title>
          <description>50-minute intravenous infusion of ketamine (0.71 mg/kg) administered during the second week of a five week regimen of motivational enhancement therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="8.3"/>
                    <measurement group_id="B2" value="50.4" spread="11.3"/>
                    <measurement group_id="B3" value="53" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group</title>
        <description>Percentage of participants demonstrating alcohol abstinence in the control (midazolam) group versus the active (ketamine) group</description>
        <time_frame>21 days post-infusion</time_frame>
        <population>Medically healthy, treatment-seeking adults without psychiatric comorbidity and who met DSM-IV criteria for alcohol dependence and minimum use criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group: Midazolam+MET</title>
            <description>50-minute intravenous infusion of the active control midazolam (0.025 mg/kg), administered during the second week of a five week regimen of motivational enhancement therapy.</description>
          </group>
          <group group_id="O2">
            <title>Active Group: Ketamine+MET</title>
            <description>50-minute intravenous infusion of ketamine (0.71 mg/kg) administered during the second week of a five week regimen of motivational enhancement therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group</title>
          <description>Percentage of participants demonstrating alcohol abstinence in the control (midazolam) group versus the active (ketamine) group</description>
          <population>Medically healthy, treatment-seeking adults without psychiatric comorbidity and who met DSM-IV criteria for alcohol dependence and minimum use criteria.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                    <measurement group_id="O2" value="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the study period and at 6 months follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group: Midazolam+MET</title>
          <description>50-minute intravenous infusion of the active control midazolam (0.025 mg/kg), administered during the second week of a five week regimen of motivational enhancement therapy.</description>
        </group>
        <group group_id="E2">
          <title>Active Group: Ketamine+MET</title>
          <description>50-minute intravenous infusion of ketamine (0.71 mg/kg) vs. 2) administered during the second week of a five week regimen of motivational enhancement therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mild agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elias Dakwar, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467748728</phone>
      <email>elias.dakwar@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

